Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.

Frontiers in endocrinology20242 citationsPMID: 38549766

Abstract

[This corrects the article DOI: 10.3389/fendo.2023.1214334.].

Zeng, Qingyue; Xu, Jiao; Mu, Xingyu; Shi, Yi; Fan, Hong; Li, Shuangqing

dual agonistsglucagon-like peptide-1 receptor agonistsincretin based therapyobesitytirzepatidetype 2 diabetes